Baricitinib vs. Placebo or Adalimumab for Rheumatoid Arthritis
Compared to placebo and adalimumab, the addition of once-daily oral baricitinib produced significant clinical improvements in RA patients, research shows.
Read More
TNFi-Methotrexate Combo Increases Odds of Achieving ACR70 in RA
Rheumatoid arthritis patients who fail previous methotrexate therapy respond better to TNFi–methotrexate combo, compared to a specific triple therapy, researchers say.